CLINICAL_TRIALS
trial_result
· 2021-06-23
Clinical Trial Update: Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) [Phase 3]
Summary
Phase 3 trial of intravitreal conbercept for neovascular age-related macular degeneration was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Chengdu Kanghong Biotech Co., Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: TERMINATED